Valuation: Legend Biotech Corporation

Market Cap 3.61B 3.22B 2.98B 2.7B 5.08B 341B 5.14B 35.71B 14.01B 179B 13.54B 13.26B 571B P/E 2026 *
-1,748x
P/E 2027 * 27.3x
Enterprise Value 2.65B 2.36B 2.19B 1.98B 3.73B 250B 3.77B 26.22B 10.29B 131B 9.94B 9.74B 419B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 1.41x
Free-Float
98.75%
Yield 2026 *
-
Yield 2027 * -
1 day+0.94%
1 week-5.25%
Current month-5.68%
1 month+0.64%
3 months-20.27%
6 months-27.65%
Current year-13.71%
1 week 18
Extreme 17.995
19.77
1 month 17.56
Extreme 17.56
20
Current year 16.24
Extreme 16.24
37.5
1 year 16.24
Extreme 16.24
37.5
3 years 16.24
Extreme 16.24
70.13
5 years 16.24
Extreme 16.24
77.32
10 years 16.24
Extreme 16.24
77.32
Manager TitleAgeSince
Chief Executive Officer 53 2026-09-14
Director of Finance/CFO 54 2025-08-17
Compliance Officer 53 2026-01-31
Director TitleAgeSince
Chairman 57 2020-11-05
Director/Board Member 69 2020-04-30
Director/Board Member 63 2020-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 Sell

Director

-27,370 0.0095%
9/24/26 Free

Director

20,986 0.0073%
9/24/26 Free

Director

28,330 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%-5.25%-41.58%-71.31% 3.61B
-4.10%-8.35%+38.48%+66.99% 66.22B
+1.02%+4.59%+11.87%+75.96% 55.2B
+0.98%+4.44%+12.61%+92.49% 52.79B
+0.67%+2.98%+28.12%+51.94% 45.53B
-1.33%+1.85%+21.52%+125.80% 43.94B
-3.40%-1.64%+251.36%+914.17% 41.64B
-1.67%+8.06%+14.17%+56.67% 34B
-8.38%-9.01%+25.65%-1.82% 25.84B
+1.30%+4.94%+38.23%+28.03% 23.51B
Average -1.41%+2.81%+40.04%+133.89% 39.23B
Weighted average by Cap. -1.48%+3.34%+47.05%+157.42%

Financials

2026 *2027 *
Net sales 1.44B 1.28B 1.19B 1.07B 2.02B 136B 2.05B 14.22B 5.58B 71.32B 5.39B 5.28B 227B 1.77B 1.58B 1.46B 1.32B 2.5B 167B 2.53B 17.55B 6.89B 88.02B 6.66B 6.52B 280B
Net income -12.18M -10.86M -10.05M -9.1M -17.14M -1.15B -17.34M -121M -47.28M -604M -45.7M -44.75M -1.93B 198M 177M 164M 148M 279M 18.71B 282M 1.96B 770M 9.84B 744M 728M 31.34B
Net Debt -959M -855M -792M -716M -1.35B -90.54B -1.37B -9.49B -3.72B -47.59B -3.6B -3.52B -152B -1.12B -994M -921M -833M -1.57B -105B -1.59B -11.04B -4.33B -55.35B -4.19B -4.1B -176B
Projected Income Statement - Annual - Legend Biotech Corporation
Logo Legend Biotech Corporation
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Employees
3,200
Date Price Change Volume
26-10-22 US$18.78 +0.81% 381,648
26-10-21 US$18.63 -2.00% 1,560,137
26-10-20 US$19.01 +1.93% 1,137,163
26-10-19 US$18.65 +0.92% 1,894,711
26-10-16 US$18.48 -6.67% 2,961,906
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Legend Biotech Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
18.63USD
Average target price
45.62USD
Spread / Average Target
+144.89%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Legend Biotech Corporation
  1. Stock Market
  2. Stocks
  3. LEGN Stock